Madeline Kelble
About Madeline Kelble
Madeline Kelble is a Procurement Specialist at Bristol Myers Squibb in Boston, Massachusetts, with extensive experience in procurement roles across multiple biotech and pharmaceutical companies.
Title
Madeline Kelble is a Procurement Specialist currently working at Bristol Myers Squibb in Boston, Massachusetts, United States. The position involves a hybrid work arrangement.
Current Role at Bristol Myers Squibb
Madeline Kelble works as a Procurement Specialist at Bristol Myers Squibb. Her responsibilities likely include managing procurement processes, vendor relationships, and strategic sourcing initiatives to support the company's operations, particularly in the biotech and pharmaceutical sectors.
Previous Positions and Expertise
Madeline has held multiple procurement-related roles in various biotech and pharmaceutical companies. She has worked at Resilience as a Site Procurement Lead and Global Procurement Analyst I, and at Rubius Therapeutics as a Buyer. Her tenure at Fusion Worldwide as a Buyer and her transition from procurement roles at Bristol Myers Squibb during the acquisition of Karuna Therapeutics underline her extensive experience. Earlier in her career, she worked in claims and customer service at Plymouth Rock Assurance.
Education and Background
Madeline studied at Boston College, where she earned a Management degree with a concentration in Marketing and Operations Management. She also studied at United South High School: The Academy of Global Business and Advanced Technology, focusing on business education. Her academic background in marketing and operations management provides her with a comprehensive understanding of procurement strategies and processes.
Experience with Bristol Myers Squibb Acquisition of Karuna Therapeutics
Madeline Kelble has been involved in the procurement aspects during the acquisition of Karuna Therapeutics by Bristol Myers Squibb. This experience showcases her ability to manage complex procurement projects and contribute to significant corporate transactions in the biotech industry.